[Considerations on treatment with SGLT2 inhibitor during acute illness]. / SGLT2-hämmare kan behöva sättas ut vid allvarliga sjukdomstillstånd.

During the last few years SGLT2 inhibitors have quickly become an important alternative in treating type 2 diabetes, heart failure and chronic kidney disease. The hallmark studies that resulted in inclusion of SGLT2 inhibitors in international treatment guidelines for these diseases excluded individuals with recent acute illness and thus the evidence on treatment in acute situations is scarce. Initiation of treatment is recommended in stable patients and not during acute illness that can increase insulin resistance and thus need for insulin. Insufficient insulin levels, due to relative or complete insulin deficiency, can lead to ketoacidosis in individuals with diabetes during treatment with SGLT2 inhibitors. Temporary discontinuation of SGLT2 inhibitors should be considered during periods of acute illness.